NeuroSense Therapeutics Faces Nasdaq Non-Compliance Notice

Neurosense Therapeutics Ltd. (NRSN) has released an update.

NeuroSense Therapeutics Ltd., a biotech firm tackling neurodegenerative diseases, has been notified by Nasdaq of non-compliance with its minimum bid price rule, as its shares traded below $1 for 30 days. The company has 180 days, until February 24, 2025, to regain compliance by maintaining a closing bid price of at least $1 for 10 consecutive days. Despite the notice, NeuroSense’s ordinary shares will continue to be listed and traded on Nasdaq during the grace period.

For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.